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We have previously demonstrated a xenograft of interleukin-6 (IL-6) overexpressing basal cell carcinoma (BCC) cell
line induced tumors with high vasculature in nude mice. Here we asked whether IL-6 could induce angiogenic
activity in BCC cell line. Tenfold concentrated conditioned medium (CM) from IL-6 overexpressing BCC cells
exhibited higher angiogenic activities in chorioallantoic membrane and Matrigel plug assays, when compared with
CM from vector control or parental BCC cells. The level of basic ﬁbroblast growth factor 2 (bFGF) mRNA and
secreted bFGF increased in IL-6 overexpressing BCC cells as shown by RT-PCR and ELISA, respectively. Con-
cordantly, recombinant IL-6 treatment caused the elevation of bFGF mRNA and protein levels in parental BCC cells
in a time-dependent manner. Neutralizing bFGF function by anti-bFGF antibody significantly inhibited CM-induced
human umbilical vein endothelial cells (HUVEC) tube formation and Matrigel plug formation. Meanwhile,
cyclooxygenase 2 (COX-2)-specific siRNA markedly abolish HUVEC tube formation. These data indicated both
bFGF and COX-2 play an essential role for IL-6-induced angiogenesis in BCC cell line. Treatment with AG490 (Janus
tyrosine kinase [JAK] inhibitor) and LY294002 (PI3-Kinase inhibitor) inhibited IL-6-mediated upregulation of bFGF
mRNA and protein secretion. Consistently, transfection with dominant negative mutants of signal transducer and
activator of transcription 3 (STAT3) and acutely transforming retrovirus AKT8 in rodent T cell lymphoma (Akt)
effectively abolished IL-6-mediated expression of bFGF mRNA and protein. Our data suggest that under in vitro
experimental condition, bFGF and COX-2 are downstream effectors of IL-6-induced angiogenic activity in BCC cell.
The IL-6-mediated bFGF upregulation is through activation of JAK/STAT3 and PI3-Kinase/Akt pathways.
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Basal cell carcinoma (BCC) is the most common skin can-
cer in humans. The incidence of BCC increases with expo-
sure to ultraviolet (UV) light, and BCC favors sun-exposed
sites of the body (Kricker et al, 1994, 1995). Both of these
facts indicate that UV light is the causal agent of BCC. Al-
though BCC generally shows a relatively benign course,
growing slowly and expanding only locally, some cases are
aggressive and can rapidly infiltrate deeper structures and
sometimes give rise to metastatic spreads (Miller, 1991).
It has been demonstrated that the in vivo expression of
interleukin-6 (IL-6) accompanies vascularization in repro-
ductive system, during wound healing, in psoriasis (in which
tortuous capillary in dermal papilla is a characteristic find-
ing), and during tumor growth (Hirano et al, 1990; Motro
et al, 1990; Elder et al, 1992; Mateo et al, 1994). These data
suggest that IL-6 may induce angiogenesis.
Tumor growth and metastasis depend upon the ability to
induce its own blood supply (Folkman and Shing, 1992). A
number of studies have reported an association between
intratumor microvessel density and tumor aggressiveness
(Weidner, 1995). The tumor vasculization was also found to
correlate with the aggressive (malignant) phenotype in hu-
man BCC (Staibano et al, 1996).
UV irradiation is considered to be a major etiological
factor for pathogenesis of BCC (Kricker et al, 1994, 1995).
Interestingly, UV irradiation can trigger the release of IL-6
and tumor necrosis factor a (TNF-a from human epidermal
keratinocytes; Avalos-Diaz et al, 1999). Our previous study
revealed that increased tumorigenicity and vascularity in
nude mice transplanted IL-6 overexpressing BCC cells. In
addition, vascular endothelial growth factor (VEGF) and
cyclooxygenase 2 (COX-2) have been found to be ex-
pressed in IL-6 overexpressing BCC cells (Jee et al, 2001). A
recent study has shown that basic fibroblast growth factor 2
(bFGF) was overexpressed in epithelial neoplasm of skin
(Arbiser et al, 2000), suggesting that bFGF may have a role
in neoplastic alteration of skin. This study is thus aimed toS.-H. Jee and C.-Y. Chu contributed equally to this work.
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Copyright r 2004 by The Society for Investigative Dermatology, Inc.
1169
investigate whether bFGF would be regulated by IL-6 and
the possible role of bFGF in IL-6 induced angiogenesis in
BCC cells. We found that IL-6 indeed upregulated bFGF
mRNA and promoted the secretion of bFGF protein in BCC
cells. In addition, IL-6-mediated angiogenic activity was
strongly attenuated by treatment with anti-bFGF antibody.
Results
IL-6 enhances angiogenesis in in vivo models We pre-
viously demonstrated that BCC/IL-6 cells were more
tumorigenic and induced more vascularization in nude mice
(Jee et al, 2001). To clarify whether IL-6 could induce the
angiogenic activity in BCC cells, we collected conditioned
medium (CM) from cells and then performed chorioallantoic
membrane (CAM) and Matrigel plug assay. CM from IL-6
overexpressing BCC cells (BCC/IL-6 or BCC/IL-6/8D cells)
produced profound neo-capillaries 3 days after loading onto
CAM as compared with that from parental BCC cells or
BCC/neo cells (Fig 1). Matrigel plug assay showed that CM
from IL-6 overexpressing cells displayed more vascularizat-
ion in plugs on the seventh day after inoculation (data not
shown). The degree of vascularization was quantitatively
measured based on the hemoglobin contents (Fig 4B).
These biological assays confirmed that IL-6 may increase
angiogenic activity in human BCC cells.
Upregulation of bFGF by IL-6 in BCC cells To dissect
whether bFGF or other possible angiogenic factor(s) may be
regulated by IL-6, we used RT-PCR to examine the expres-
sion level of various angiogenic factors (bFGF, platelet-de-
rived growth factor (PDGF), and IL-8) that have previously
been reported to be important in activating angiogenesis.
Only bFGF mRNA was elevated in IL-6 overexpressing BCC
cells (Fig 2A). Correlating with the mRNA level, IL-6 over-
expressing cells secreted a significant amount of bFGF
protein (Fig 2B). We further confirm exogenous IL-6 treat-
ment enhanced bFGF expression in the parental BCC cells.
RT-PCR analysis showed a time-dependent increase in
bFGF mRNA in BCC cells after treatment with IL-6 (Fig 3A).
ELISA analysis revealed that IL-6 stimulation gradually in-
creased the level of secreted bFGF at 4–24 h and peaked
(3.3-fold) at 48 h in BCC cells (Fig 3B). Secreted VEGF was,
however, upregulated to 1.36-fold only. Supportively, West-
ern blot analysis of cell lysates from IL-6-treated BCC cells
revealed that either high molecular weight (HMW) or low
molecular weight (LMW) bFGF was significantly elevated at
4–16 h after IL-6 treatment (Fig 3C).
Neutralization of bFGF in CM and transfection of COX-2-
specific siRNA into IL-6 over-expressing BCC cells in-
hibits IL-6-induced angiogenic activities Our previous
study shows that IL-6 induces VEGF and COX-2 in BCC
cells (Jee et al, 2001). To clarify the biological function of
bFGF, VEGF, and COX-2 in IL-6-mediated angiogenesis, we
used anti-bFGF and anti-VEGF neutralizing antibody and
transfection of COX-2 siRNA, respectively, to block their
function and examined the angiogenic activity by using
Figure 1
Increase in angiogenic activity in basal cell carcinoma (BCC) cells
overexpressing interleukin-6 (IL-6). The condition media collected
from parental BCC cells (BCC), control vector transfectant (BCC/Neo),
pooled IL-6 transfectant (BCC/IL-6) and IL-6 transfectant with highest
IL-6 expression (BCC/IL-6/8D) for chorioallantoic membrane (CAM)
assay on Leghorn chicken eggs for 3 d. This represents one of three
experiments.
Figure2
Upregulation of basic fibroblast growth factor 2 (bFGF) in basal cell
carcinoma (BCC) cells over-expressing interleukin-6 (IL-6). (A) After
serum starvation, the mRNA of various cell lines as indicated were ex-
tracted and semiquantified by RT-PCR of bFGF, platelet-derived growth
factor (PDGF), and IL-8. The number below each lane indicates the rel-
ative densitometric intensity to control (defined as 1.0). This represents
one of three experiments. (B). Cell-free culture supernatant was analyzed
for bFGF by ELISA. Concentration of bFGF was expressed as mean  SD
of five experiments. Student’s t test was used for comparison.
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human umbilical vein endothelial cells (HUVEC) capillary
tube formation on Matrigel. Exposure of HUVEC to CM from
BCC/IL-6 or BCC/IL-6/8D resulted in tube formation that
was significantly inhibited by neutralizing with anti-bFGF but
not anti-VEGF antibody (83.1% and 14.9% inhibition, re-
spectively). (Fig 4A, left). The protein lysate from BCC/IL-6/
8D cells transfected with COX-2-specific siRNA was col-
lected for western blotting to ensure the abrogation of 50%
of Cox-2 (data not shown). The CM collected from COX-2-
specific siRNA transfectant caused 62% inhibition of cap-
illary tube formation compared with that of BCC/IL-6/8D
cells. (Fig 4A, right). The results suggest that bFGF and
COX-2 are possibly the main downstream effectors induced
by IL-6 in the angiogenesis of BCC.
Direct treatment of HUVEC with IL-6 cytokine did not
induce tube formation significantly (data not shown). In ad-
dition, anti-IL-6 antibody also failed to affect the tube for-
mation induced by CM from IL-6 overexpressing cells (data
not shown), suggesting that tube-forming activity of CM
from IL-6 overexpressing cells was not directly caused by
IL-6.
Using Drabkin method for quantitation of the total hemo-
globulin in Matrigel gel plug assay, we showed that treat-
ment with anti-bFGF antibodies caused 85% inhibition on
the total amount of hemoglobin (Fig 4B). This confirmed that
bFGF contributed to the IL-6-induced angiogenic activity in
BCC cells.
JAK/STAT3 and PI3-Kinase/Akt signal pathways are in-
volved in IL-6 induced upregulation of bFGF Three major
signaling pathways including the JAK/STAT3 pathway, PI3-
Kinase/Akt pathway, and mitogen-activated protein kinase
(MAPK) pathway (Heinrich et al, 2003) have been reported
to be involved in the IL-6-mediated cellular functions. Ini-
tially, pharmacological inhibitors such as AG490 (a JAK in-
hibitor, 50 mM), LY294002 (a PI3-Kinase inhibitor, 25 mM), or
PD98059 (a MEK inhibitor, 50 mM) were used to examine
which pathways were involved in IL-6-mediated bFGF up-
regulation in BCC cells. The optimal doses used to specif-
ically inhibit the signaling pathways by these inhibitors were
described in our previous study (Jee et al, 2002). RT-PCR
analysis revealed that IL-6-mediated increase of bFGF
mRNA was significantly attenuated by AG490 and
LY294002 but not by PD98059 (Fig 5A). Both AG490 and
LY294002 effectively reduced the amount of secreted bFGF
protein in BCC cells stimulated by IL-6, as determined by
ELISA (Fig 5B). These data suggest that PI3K/Akt and JAK/
STAT3 are coordinately involved in IL-6-mediated bFGF
gene expression in BCC cells. Consistently, transfection
with dominant-negative STAT3 mutants (STAT3F and
STAT3D) and Akt mutant (dnAkt) into BCC cells caused a
strong inhibition on IL-6-stimulated bFGF mRNA and pro-
tein level. (data not shown).
Together, our study revealed that IL-6 induced angio-
genesis in BCC by upregulation of secreted bFGF via both
JAK/STAT3 and PI3-Kinase/Akt pathways and by COX-2.
Discussion
IL-6 has been implicated in the pathogenesis of multiple
myeloma and some other malignancies, including renal cell
carcinoma, prostate cancer, and Kaposi’s sarcoma (Akira
and Kishimoto, 1992; Aoyagi et al, 1996; Adler et al, 1999;
Aoki et al, 1999; Kinoshita et al, 1999). Our previous study
has demonstrated that transplantation of IL-6 overexpress-
ing BCC cells into nude mice resulted in the enhancement
of tumor growth accompanied by high vascularization (Jee
Figure 3
Time dependent upregulation of mRNA, protein and secretion of
basic fibroblast growth factor 2 (bFGF) in basal cell carcinoma
(BCC) cells stimulated with interleukin-6 (IL-6). (A) After serum star-
vation, the parental BCC cells were incubated in the presence of 100 ng
per mL human recombinant interleukin-6 (rIL-6) for different times as
indicated. The mRNA extracted was semiquantified by RT-PCR for
bFGF and vascular endothelial growth factor (VEGF). (B) The protein
extracted from cell lysates were quantified by Western blotting for
bFGF. The number below each lane indicates the relative densitometric
intensity to control (defined as 1.0). This represents one of three ex-
periments. High molecular weight (HMW: 24, 22.5 kDa) and low mo-
lecular weight (LMW: 18 kDa) bFGF are shown in upper, mid-, and
lower row, respectively. (C) The secretion of bFGF in the culture supe-
rnatant was measured by ELISA. Concentration of bFGF was ex-
pressed as mean  SD of five experiments. Student’s t test was used
for comparing the paired cultured cells with and without stimulation
with IL-6 at various time as indicated.
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et al, 2001). Here we provide evidence to show that ex-
ogenous IL-6 stimulation can upregulate the bFGF mRNA
expression and protein secretion in BCC cells whereas IL-8
and PDGF are not affected by IL-6. Blockage of bFGF
function by neutralizing antibody strongly prevented IL-6-
mediated angiogenic activities as seen in HUVEC tube for-
mation, and Matrigel plug assay. Our data revealed that
bFGF is a downstream effector of IL-6-induced angiogen-
esis in BCC cell line cells under in vitro condition.
bFGF is a multifunctional protein with well-studied mi-
togenic and angiogenic properties (Basilico and Moscatelli,
1992). It is a protein devoid of secretory signal sequence. At
variance with VEGF, bFGF is released via an alternative
ATP-dependent secretion pathway independent of the
endoplasmic reticulum–Golgi complex (Florkiewicz et al,
1998). During the development of fibrosarcoma in a trans-
genic mouse model, the appearance of an angiogenic
phenotype is correlated with the export of bFGF (Kandel
et al, 1991). A secreted FGF binding protein that mobilizes
stored extracellular bFGF can serve as an angiogenic
switch for different cell lines including squamous cell car-
cinoma (SCC) and colon cancer cells (Czubayko et al,
1996). Interestingly, bFGF has been shown to affect early
tumor angiogenesis but without any effect in established
Figure 4
Blockage of basic fibroblast growth factor 2 (bFGF) function or cyclooxygenase 2 (COX)-2 inhibited angiogenesis induced by interleukin-6
(IL-6). (A) 1 mg anti-bFGF or anti-vascular endothelial growth factor (VEGF) antibody was pre-incubated with 150 mL condition medium (CM) of BCC/
IL-6/8D for 30 min. before incubation with human umbilical vein endothelial cells (HUVEC) cells. CM collected from BCC/IL-6/8D cells transfected
with vector containing COX-2 siRNA was incubated with HUVEC cells. (The number of tube-like structures was expressed as mean  SD of
randomly counting five 9.7 mm2 microscopic fields. n¼3) (B) CM neutralized with anti-bFGF antibody was served for Matrigel blood plug assay in
C57BL6j mice (five per group). The blood plugs were extracted and quantization of hemoglobulin was performed using the Drabkin method. The
mean amount of hemoglobulin was calculated. Student’s t test was used for comparison. NS: non-significant.
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tumors (Giavazzi et al, 2001). Our study reveals that the
secreted bFGF was responsible for IL-6-induced angiogen-
esis; however, whether the elevation of bFGF contributes to
IL-6-induced tumor growth in BCC is unknown and needs
to be clarified. The paracrine tumor–stromal cell interaction
of VEGF and IL-6 in multiple myeloma has been reported
(Dankbar et al, 2000). This study indicates the crucial role of
bFGF in IL-6-induced angiogenesis in BCC cells.
bFGF has been detected in normal skin, benign epider-
mal proliferation, and malignant neoplasm of skin (Yaguchi
et al, 1993; Arbiser et al, 2000). Sun exposure is the essen-
tial causal factor of BCC. A single exposure to UVB irradi-
ation can induce erythema, epidermal hyperplasia, and
increased cutaneous vasculization. IL-6 is one of the pro-
inflammatory cytokines induced by UV irradiation in kera-
tinocytes (Schwarz and Luger, 1989; Chung et al, 1996).
UVB induced cutaneous angiogenesis in C3H/HeN mice
via upregulation of bFGF, but not VEGF, on day 1 of UVB
irradiation (Bielenberg et al, 1998). Concordantly, our data
demonstrated that bFGF was markedly upregulated by IL-6
in BCC cells.
Accumulating evidence is defining a critical role for
STAT3 in oncogenesis (Bowman et al, 2000; Catlett et al,
1999a, b). Constitutive activation of STAT3 signaling con-
tributes to oncogenesis by preventing apoptosis and en-
hancing cell proliferation (Grandis et al, 1998, 2000; Catlett
et al, 1999a, b; Bowman et al, 2000). Similarly, PI3-Kinase/
Akt pathway has been reported to play a major role in ago-
nist-induced cell survival and growth (del Peso et al, 1997;
Blume-Jensen, 1998; Vanhaesebroeck and Alessi et al,
2000). We previously demonstrated the anti-apoptotic ac-
tivity of both STAT3 and PI3-Kinase/Akt in BCC cells or BCC
cells stimulated with IL-6. We reported previously that cer-
vical tumor growth promotion by IL-6 in VEGF-dependent
angiogenesis via a STAT3 pathway (Wei et al, 2003). In this
study bFGF was upregulated via JAK/STAT3 and PI 3-Kin-
ase/Akt pathways in BCC cells stimulated with IL-6. It has
been shown that 5(S)-hydroxyeicosatetraenoic acid stimu-
lates autocrine growth of HUVEC via activation of JAK/STAT
and PI3-Kinase/Akt signal leading to activation of bFGF
(Zeng et al, 2002). Our study demonstrated that IL-6 stim-
ulates secretion of bFGF via similar pathways to act on
HUVEC cells in a paracrine mode. These data suggest that
activation of JAK/STAT/bFGF and PI3-Kinase/Akt/bFGF
pathways in either tumor cells (paracrine mode) or end-
othelial cells (autocrine mode) leads to angiogenesis.
Finally, our study revealed that IL-6 induced angiogen-
esis in BCC by upregulation of secreted bFGF via both JAK/
STAT3 and PI3-Kinase/Akt pathways. This finding suggests
prevention of IL-6 production (e.g., avoid exposure to UV
light or usage of anti-inflammatory drugs), inhibition of bFGF
production or secretion, or blockage of the JAK/STAT3 and
PI3-Kinase/Akt signal pathways may be the feasible man-
agement for prevention or treatment of skin cancer. In ad-
dition, our data also showed that blockage of Cox-2 by
siRNA reduced angiogenic activity in IL-6 overexpressing
BCC cells, suggesting that Cox-2 also play a role in IL-6-
induced angiogenesis.
Materials and Methods
All the described study was approved by the medical ethical com-
mittee of National Taiwan University College of Medicine and was
conducted according to Declaration of Helsinski Principle.
Cell origin, cell culture, and establishment of IL-6 transfect-
ants The human BCC cell line (parental BCC cells), originally
named BCC-KMC-1, was originated from an undifferentiated BCC
derived from a trauma scar. Using keratinocytes cultured in serum-
free medium as positive control, we performed RT-PCR to measure
the expression of K14 mRNA in BCC cells. The basaloid keratin-
ocytes nature of this BCC cell line is verified by the presence of
keratin 14 mRNA by RT-PCR method in these BCC cells, but not in
Hela cells.
The 105–108th passages of this cell line were used in this study.
The pCMV-IL-6, a constitutive expression vector, carries 0.64 kb
full-length human IL-6 cDNA under the control of the CMV pro-
moter/enhancer sequence and with a neomycin selection marker.
The BCC cells were transfected with pCMV-IL-6 or control pcDNA3
vector (GIBCO Invitrogen, Grand Island, New York), containing a
CMV promotor and a neomycin selection marker, using the Trans-
Fast transfection reagent (Promega, Madison, Wisconsin). After
24 h, cells were replated in RPMI 1640 medium (GibcoBRL,
Rockville, Maryland) with 10% fetal calf serum (FCS) and 500 ng
per mL G418 (Sigma, St Louis, Missouri). G418-resistant clones
were selected and expanded. For this study, we used the pooled
transfectants (BCC/IL-6) and the highest expression transfectant
(BCC/IL-6/8D), with IL-6 secretion of about 832 and 1427 pg per
mL, respectively. The parental BCC cells and BCC cells trans-
fected with control vector, BCC/Neo cells, served as controls. All
these cells were grown at 371C and 5% CO2 in RPMI 1640 medium
supplemented with 10% (vol/vol) fetal bovine serum (FBS).
Figure 5
AG490 (JAK inhibitor) and LY294002 (PI3-Kinase inhibitor) reduced
interleukin-6 (IL-6) upregulated expression and secretion of basic
fibroblast growth factor 2 (bFGF) in basal cell carcinoma (BCC)
cells. After pre-treating with human recombinant interleukin-6 (rIL-6)
(100 ng per mL) for 15 min, BCC cells were serum starved for 72 h and
treated with AG490 or LY294002 or PD98059 (MEK inhibitor) for 8 more
hours. (A) The mRNA of BCC cells with various treatment were semi-
quantified by RT-PCR for bFGF. The number below each lane indicated
the relative intensity of bFGF mRNA to controls (defined as 1.0). This is
one representative experiments of three. (B) The culture supernatants
were subjected to ELISA with bFGF antibody. The concentration of
bFGF was expressed as mean  SD of five experiments. Student’s t
test was used for comparison. NS: non-significant.
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Antibodies and reagents Affinity-purified monoclonal mouse an-
ti-bFGF antibody was purchased from BD Bioscience (San Diego,
California). Anti-a-tubulin antibody was from NeoMarkers (Fre-
mont, California). Neutralizing antibodies (mouse monoclonal anti-
IL-6 antibodies and goat polyclonal anti-bFGF antibody) were from
R&D Systems (Minneapolis, Minnesota). AG490 (JAK inhibitor),
LY294002 (LY, PI3-Kinase inhibitor), and PD98059 (MEK inhibitor)
were from Calbiochem (San Diego, California).
Preparation of CM Parental BCC, BCC/Neo, BCC/IL-6, or BCC/
IL-6/8D cells were plated in 1 mL culture medium without serum at
2  105 cells per well in 24-well 18 mm culture dishes. The culture
supernatants were collected 24 h later and centrifuged sequentially
at 12,500 g with Microcon YM-3 centrifugal filter devices (cut-
off molecules smaller than 3000 Da; Millipore, Bedford, Massa-
chusetts) for 10 min to obtain a 10-fold concentrate culture
supernatant.
CAM assay Nine-day-old fertilized White Leghorn chicken eggs
were incubated at 371C at constant humidity. On incubation day 3,
a square window was opened on the shell and sealed with a glass.
On day 11, 1 mm3 filter papers loaded with 30 mL CM were im-
planted on top of the CAM. Capillary tube formations were exam-
ined 3 days later, when the angiogenic response peaked. The
blood vessels entering the paper were recognized macroscopically
and photographed.
In vivo Matrigel blood plug assay Matrigel blood plug assay was
performed as described previously (Plunkett and Hailey, 1990;
O’Reilly et al, 1997). Briefly, C57BL6j mice (five per group) were
each injected subcutaneously with 50 mL of CM from various cell
lines mixed with 450 mL Matrigel L (growth factor reduced; Becton
Dickinson Labware, Bedford, Massachusetts) and 40 U heparin per
mL at 4oC. Mice were sacrificed 6 d later, and gels were recovered
and processed for further studies. Neovessels was quantified by
Drabkin method, measuring hemoglobin of the plug with Drabkin
reagent kit 525 (Sigma). Experiment was authorized by animal
experiment committee of National Taiwan University College of
Medicine.
Cox-2-specific RNA interference Target sequence for the COX-2
siRNA was bases 291–313 of NM000963.1 (50 aactgctcaaca-
ccggaattttt30). PRNA-U6/neo (GenScript, Piscataway, New Jersey)
is a siRNA expression vector with neomycin as selection marker.
We construct pRNA-U6/COX-2, a constitutively expressed vector
that carries the COX-2 siRNA sequence under the control of U6
promotor. The BCC/IL-6/8D cells were transiently transfected with
pRNA-U6/COX-2 overnight. The CM was collected for capillary
tube formation assay.
In vitro capillary tube formation on Matrigel Human umbilical
vein was collected with consent form. HUVEC capillary tube for-
mation was evaluated as follows. 24-well 18 mm tissue culture
dishes were coated with Matrigel basement membrane matrix (300
mL per well; Becton Dickinson Labware) at 41C and allowed to
polymerize at 371C for at least 30 min. HUVEC (2  105 cells per
well) were grown in a final volume of 0.30 mL culture medium
containing 150 mL M199 (GibcoBRL) and 150 mL CM. After 6 h
incubation, tube formation was observed through a reverted,
phase-contrast photomicroscope photographed and counted. The
number of tube formations was measured by counting the number
of tube like structures formed by connected endothelial cells in
five randomly selected 9.7 mm2 microscopic fields. The assay was
performed in triplicate.
Construction of dominant-negative DNA and transient
transfection For assay of JAK/STAT3 signal pathway, we con-
structed hemagglutinin (HA) epitope-tagged dominant-negative
STAT3 mutants. An HA epitope tag was inserted into STAT3F
(Nakajima et al, 1996) cDNA or STAT3D (Horvath et al, 1995) cDNA
and cloned into a pcDNA3 vector (GIBCO Invitrogen). BCC cells
were plated 12 h before transfection at a density of 1  105 cells
per 6 cm Petri dish, followed by transfection with 1 mg of STAT3F
plasmid or STAT3D plasmid using the Transfast Transfection Re-
agent (Promega) as per manufacturer’s instructions. The amount of
HA was concomitantly measured to confirm the transfection effi-
ciency. Dominant-negative mutant of Akt was similarly constructed
and transfected as described above.
RT-PCR Messenger RNAs from BCC cells treated with IL-6 were
isolated using commercial kits (Promega). The total RNA was sub-
jected to first-strand synthesis using Random Hexamer (Promega)
and M-MLV Reverse Transcriptase (RNase H Minus) (Promega) at
371C for 3 h. The cDNA was then diluted to a final volume of 50 mL
and quantified. PCR reactions contained 5 mg cDNA, 0.5 U per mL
Taq polymerase (Protech Technology, Taiwan), and 25 pmol each
of the sense and the anti-sense primers in PCR buffer (10 mM Tris
pH 9, 50 mM KCl, 6 mM MgCl2, 0.01% gelatin, and 0.1% Triton X-
100). The reaction mixture was incubated for 5 min at 941C and
then amplified by 25 PCR cycles (denaturation for 1 min at 941C,
annealing for 1 min at 561C, and extension for 1 min at 721C). Each
PCR product was then analyzed on a 2% agarose gel stained with
1 mg per mL ethidium bromide and photographed (Digital Science
SP700 camera; Kodak Scientific Imaging Systems, New Haven,
Connecticut). Intensity of bands on the photographs was quanti-
fied by scanning laser densitometry.
Enzyme immunoassay (ELISA) The bFGF and VEGF levels of the
cell culture supernatant were determined by using commercially
available ELISA kits (R&D Systems) according to the manufactur-
er’s instructions. Each measurement was repeated in triplicate, and
the average value was recorded as pg per mL.
Western blot analysis The cellular lysates were prepared as de-
scribed previously (Kuo et al, 1998). Lysate samples (50 mg from
each lysate) were subjected to electrophoresis on 15% SDS-po-
lyacrylamide gels and were electroblotted on nitrocellulose papers.
After blocking, blots were incubated with horseradish peroxi-
dase-conjugated mouse anti-bFGF antibody (BD PharMingen, San
Diego, California) in PBST (phosphate-buffered saline containing
Triton X-100) for 1 h followed by three washes (15 min each) in
PBST. After washing, blots were incubated with the Western blot-
ting reagent ECL (Amersham Pharmacia Biotech, Little Chalfont,
Buckinghamshire, England) for 1 min. Chemiluminescence was
detected by exposure of Kodak-BioMax films to the blots for 10 s and
5 min for HMW and LMW bFGF, respectively. Intensity of bands on
autoradiograms were quantified by scanning laser densitometry.
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